New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
09:39 EDTPBYI, GSKASCO data shows 'challenges' to Puma's neratinib
Citigroup believes data presented over the weekend at ASCO showed 'some challenges' to Puma Biotechnology's (PBYI) neratinib. Citi says the failed ALLTO trail announced by GlaxoSmithKline (GSK) shows how difficult it is to show a benefit in the adjuvant setting. Citi added that its cautious on the outcome for neratinib is the adjuvant ExteNET setting. Shares of Puma are down 17% to $63.70 in early trading. Citi keeps a Buy rating on the stock with a $123 price target.
News For PBYI;GSK From The Last 14 Days
Check below for free stories on PBYI;GSK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
09:33 EDTGSKGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
09:17 EDTGSK, PBYIOn The Fly: Pre-market Movers
Subscribe for More Information
07:48 EDTPBYIPuma Biotechnology price target raised to $300 from $144 at Leerink
Subscribe for More Information
07:47 EDTPBYIPuma Biotechnology price target raised to $325 from $125 at UBS
Subscribe for More Information
07:19 EDTGSKGenmab reports Q2 Arzerra net sales GBP 12.8M
Subscribe for More Information
07:12 EDTGSKGlaxoSmithKline lowers 2014 core EPS outlook to 'similar' to 2013
GSK now expects 2014 core EPS to be "broadly similar" to 2013 versus previous expectations of 4%-8% growth. It added, "Given impact of recent sustained strength of Sterling on free cash flow, share repurchases over balance of 2014 likely to be immaterial."
07:09 EDTGSKGlaxoSmithKline reports Q2 core EPS down 12% to 19.1p
Subscribe for More Information
07:09 EDTGSKMylan wins restraining order against Apotex for generic version of GSK's Paxil
Subscribe for More Information
06:32 EDTPBYIPuma Biotechnology a likely acquisition target after data, says Citigroup
Citigroup raised its price target for Puma Biotechnology shares to $292 from $99 after the company announced positive Phase III data for its investigational breast cancer drug neratinib. Citi views Puma as a likely acquisition target saying the drug is likely to work in lung cancer and potentially other HER2mut cancers while the company has patent protection until 2030. The firm thinks Puma could be worth $291-$351 per share in a takeout scenario and keeps a Buy rating on the stock.
06:25 EDTPBYIPuma Biotechnology volatility is expected to move on positive top line results
Subscribe for More Information
July 22, 2014
18:33 EDTPBYIOn The Fly: After Hours Movers
UP AFTER EARNINGS: Broadcom (BRCM), consensus up 3% after reporting second quarter results... Intuitive Surgical (ISRG), up 10.4%... Manhattan Associates (MANH), up 3%... Robert Half International (RHI), up 3.9%... Hawaiian Holdings (HA), up 3.1%... Microsoft (MSFT), up just under 1%... FMC Technologies (FTI), up 1.1%. ALSO HIGHER: Ballard Power Systems (BLDP), up 2.7% following purchase order from New Flyer Industries... Unwired Planet (UPIP), up 2.4% after filing a lawsuit against Microsoft for breach of contract. NOTABLE: Puma Biotechnology (PBYI), up 193.8% after reporting positive top line results from Phase III PB272 trial. DOWN AFTER EARNINGS: Xilinx (XLNX), down 8.7%... Apple (AAPL), down after reporting third quarter results and fourth quarter guidance... Juniper Networks (JNPR), down 4.7%... ALSO LOWER: Farmland Partners (FPI), down 3.8% after filing to sell 3.72M shares of common stock.
16:45 EDTPBYIPuma Biotechnology up 200% after positive top line PB272 trial results
Subscribe for More Information
16:27 EDTPBYIPuma Biotechnology reports positive top line results from Phase III PB272 trial
Subscribe for More Information
16:18 EDTPBYIPuma Biotech now responsible for R&D expenses associated with legacy trials
Subscribe for More Information
09:55 EDTGSKLupin, private equity funds weigh bids for GSK's older drugs, Reuters reports
Subscribe for More Information
July 21, 2014
07:11 EDTGSKInternational Society of DNA Vaccines to hold a conference
Subscribe for More Information
July 17, 2014
07:18 EDTGSKMylan wins motion to enjoin GlaxoSmithKline from production of generic product
Subscribe for More Information
06:23 EDTGSKGlaxoSmithKline admits to bribing Chinese officials in 2001, FT reports
Subscribe for More Information
July 16, 2014
07:14 EDTGSKIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.
05:38 EDTGSKGSK, Theravance initiate Phase III IMPACT study
GlaxoSmithKline (GSK) and Theravance (THRX) announced the start of a global phase III study, known as IMPACT, to evaluate the efficacy and safety of the 'closed' triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease, or COPD. IMPACT is the first pivotal phase III study in a programme to evaluate a once-daily closed triple combination treatment of an inhaled corticosteroid, or ICS; a long-acting muscarinic antagonist, or LAMA; and a long-acting beta2-adrenergic agonist, or LABA, in patients with COPD. The IMPACT study will enrol approximately 10,000 patients and assess whether the combination of FF, or fluticasone furoate, an ICS, UMEC, or umeclidinium, a LAMA, and VI, or vilanterol, a LABA, all delivered in GSK's Ellipta inhaler, can reduce the annual rate of moderate and severe exacerbations compared with two approved once daily COPD treatments, Relvar/Breo Ellipta, FF/VI, which is an ICS/LABA combination, and Anoro Ellipta, UMEC/VI, which is a LAMA/LABA combination.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use